JAK3 inhibitors in organ transplantation and autoimmune disease.

Recent Pat Inflamm Allergy Drug Discov

Laboratory of Experimental Surgery, Department of Surgery, Research Centre, Centre hospitalier de l'Université de Montréal (CHUM), Hôpital Notre-Dame, and Université de Montréal, Montreal, Quebec, Canada.

Published: January 2010

Janus kinase 3 (JAK3) is a cytoplasmic tyrosine kinase associated with the common gamma chain that is activated by multiple T-cell growth factors including IL-2, -4, -9, -15, and -21. From the recent reports, genetic absence or ablation of JAK3 is associated with defective T-cell immunity that results in severe combined immunodeficiency (SCID) and pharmacological inhibition has prolonged allograft survival in some models of organ transplantation. This review would provide an overview of some patents along with the role of JAK3 in the immune system and efficacy of JAK3 inhibitors in experimental allograft rejection and autoimmune disease.

Download full-text PDF

Source
http://dx.doi.org/10.2174/187221310789895577DOI Listing

Publication Analysis

Top Keywords

jak3 inhibitors
8
organ transplantation
8
autoimmune disease
8
jak3
5
inhibitors organ
4
transplantation autoimmune
4
disease janus
4
janus kinase
4
kinase jak3
4
jak3 cytoplasmic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!